Abstract
In the United States, about 22,000 women will be diagnosed with ovarian cancer in 2011, and an estimated 14,000 patients will succumb to the disease [1]. Surgery and chemotherapy present the main treatment modalities, but despite the development of novel therapies, the overall 5 years survival for ovarian cancer patients with advanced disease at diagnosis remains at only about 30%. Novel therapeutic strategies are needed to prolong survival and achieve greater cure rates.
Matrix metalloproteinases (MMPs) are frequently expressed in ovarian cancer, and play an important role in the metastatic process. MMPs mediate degradation of the basement membrane as a crucial step in epithelial transformation, ovarian tumorigenesis and intraperitoneal metastasis [2]. Various preclinical and clinical studies have demonstrated that MMPs might provide a suitable therapeutic target. This review summarizes important observations regarding the expression of MMPs in ovarian cancer, their biological role, and data from clinical trials targeting MMPs in ovarian cancer patients.
Keywords: Batimastat, Clinical trial, Intraperitoneal, Ovarian cancer, Matrix metalloproteinase (MMP), Metastatic, Peptomimetic, Prinomastat, Serum marker, Tanomastat, Tissue Inhibitor of metalloproteinases (TIMP).
Anti-Cancer Agents in Medicinal Chemistry
Title:MMPs in Ovarian Cancer as Therapeutic Targets
Volume: 12 Issue: 7
Author(s): Amer Karam and Oliver Dorigo
Affiliation:
Keywords: Batimastat, Clinical trial, Intraperitoneal, Ovarian cancer, Matrix metalloproteinase (MMP), Metastatic, Peptomimetic, Prinomastat, Serum marker, Tanomastat, Tissue Inhibitor of metalloproteinases (TIMP).
Abstract: In the United States, about 22,000 women will be diagnosed with ovarian cancer in 2011, and an estimated 14,000 patients will succumb to the disease [1]. Surgery and chemotherapy present the main treatment modalities, but despite the development of novel therapies, the overall 5 years survival for ovarian cancer patients with advanced disease at diagnosis remains at only about 30%. Novel therapeutic strategies are needed to prolong survival and achieve greater cure rates.
Matrix metalloproteinases (MMPs) are frequently expressed in ovarian cancer, and play an important role in the metastatic process. MMPs mediate degradation of the basement membrane as a crucial step in epithelial transformation, ovarian tumorigenesis and intraperitoneal metastasis [2]. Various preclinical and clinical studies have demonstrated that MMPs might provide a suitable therapeutic target. This review summarizes important observations regarding the expression of MMPs in ovarian cancer, their biological role, and data from clinical trials targeting MMPs in ovarian cancer patients.
Export Options
About this article
Cite this article as:
Karam Amer and Dorigo Oliver, MMPs in Ovarian Cancer as Therapeutic Targets, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (7) . https://dx.doi.org/10.2174/187152012802650174
DOI https://dx.doi.org/10.2174/187152012802650174 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stem Cells and Nanoparticles in Therapy
Nanoscience & Nanotechnology-Asia Lgr5 Contributes to Intestinal Metaplasia During Gastric Carcinogenesis: A Meta analysis
Anti-Cancer Agents in Medicinal Chemistry Discovery and Development of Purine-Scaffold Hsp90 Inhibitors
Current Topics in Medicinal Chemistry Imaging Virus-Associated Cancer
Current Pharmaceutical Design Diffuse Large B-Cell Lymphoma with Involvement of the Chest Wall
Current Respiratory Medicine Reviews Synthesis of New Dihydroquinopimaric Acid Analogs with Nitrile Groups as Apoptosis-Inducing Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies
Current Cancer Drug Targets Pharmacogenetics of Irinotecan Disposition and Toxicity: A Review
Current Clinical Pharmacology Mechanisms of Cellular Resistance to Camptothecins
Current Medicinal Chemistry Current Innovations in Laparoscopy
Current Women`s Health Reviews Red-Fluorescent Activatable Probes for the Detection of Hydrogen Peroxide in Living Cells
Combinatorial Chemistry & High Throughput Screening Patent Selections:
Recent Patents on Drug Delivery & Formulation Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment
Current Cancer Drug Targets Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy
Current Pharmaceutical Design A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry A Phase I Study of OMN54 (Aneustat™) in Patients with Advanced Malignancies
Clinical Cancer Drugs Regulation of Expression and Function of IDO in Human Dendritic Cells
Current Medicinal Chemistry Novel Drugs Targeting Microtubules: the Role of Epothilones
Current Pharmaceutical Design MicroRNAs and Cancer Therapy – From Bystanders to Major Players
Current Medicinal Chemistry